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Abstract. Classic Hodgkin Lymphoma (cHL) has a unique histology since only a few neoplastic cells 
are surrounded by inflammatory accessory cells that in the last years have emerged as crucial 
players in sustaining the course of disease. In addition, recent studies suggest that the abnormal 
activity of these inflammatory cells (such as deregulation in regulatory T cells signaling, expansion 
of myeloid derived suppressor cells, HLA-G signaling and natural killer cells dysfunction) may 
have prognostic significance. This review is focused on summarizing recent advanced in 
immunological defects in cHL with translational implications. 
Introduction. In the classic Hodgkin's lymphoma 
(cHL) microenvironment, a few neoplastic cells - 
Hodgkin and Reed-Stemberg (HRS) cells- grow in a 
contest of a tissue rich in immune system cells, 
including fibroblasts, eosinophils, lymphocytes, 
histiocytes, neutrophils and monocytes.
1
 These immune 
system cells are unable of mounting effective anti-
tumor immune responses and, on the contrary, even 
stimulate and promote the growth of HRS cells. 
The strong correlation between classic HL (cHL) 
and Epstein-Barr virus (EBV) infection strengthens the 
hypothesis that alterations in the mechanisms involved 
in viral clearance (antigen presentation, innate natural 
killer cell-dependent immune response) may influence 
the onset of cHL. 
For its peculiar histology cHLis an extremely 
interesting study model for the assessment of 
immunogenetic factors that may confer susceptibility 
to tumours or, alternatively, facilitate tumour immune 
escape mechanisms. 
After the demonstration of the prognostic 
significance of Interim-2-[18F]Fluoro-2-deoxy-D-
glucose Positron Emission Tomography (PET-2) 
performed in the mid of chemotherapy, the role of 
accessory cells in cHL has been evaluated with 
increased interest. In fact, it has been demonstrated that 
PET-2 positivity is mainly due to the Fluoro-2-deoxy-
D-glucose uptake by the accessory cells rather than the 
HRS cells.
2
 
Inflammation-related accessory cells can be 
indirectly evaluated in the peripheral blood as well: 
several reports investigated the prognostic impact of 
the ALC/AMC-DX ratio, obtained by dividing the 
absolute lymphocyte count (ALC) over the absolute 
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monocytes count (AMC) from the complete blood 
count, as a surrogate of host immune homeostasis and 
tumour-associated macrophages (TAM) respectively, 
with contrasting results.
3, 4
 
This review is focused on the novel advances about 
the role of myeloid and lymphoid subsets involved in 
sustaining HRS and favouring immune-escape. 
 
NK Dysregulation. Natural killer (NK) cells represent 
a key component of the innate immune system against 
cancer.  
Together with NK cells, a subset of CD1d-restricted 
Natural Killer-T cells (NKT) exhibits direct anti-
tumour activity and enhances cytotoxicity of NK and 
CD8+ T cells. NKT cells are distinct lymphocyte 
population characterized by the expression of CD3 and 
CD56 and an invariant T-cell receptor (TCR) formed 
by the Ja18-Va24 and Vb11 rearrangements specific 
for glycosphingolipids presented by the non-classical 
MHC Class-I molecule CD1d.
5
 
A common immune escape strategy of HRS cells is 
to down-regulate the expression of human leukocyte 
antigen (HLA) -A,-B and -C (classic: MHC Ia) and to 
modify the expression of HLA-G and E (no classical: 
MHC Ib), as seen in about 20% and 80% of primary 
cases of EBV+ and EBV- cHL, respectively. However, 
because communication through MHC Ia-specific 
inhibitory receptors on NK cells is lacking, 
downregulation of MHC Ia generally leads to the 
activation of NK cells.
6
 
The paucity of NK cells in the reactive infiltrate of 
cHL and the systemic NK cell deficiency observed in 
cHL patients prompted further investigation into the 
immune-modulatory mechanisms of NK receptors such 
as the NKG2D activating receptor of the C-type lectin 
superfamily, killer immunoglobulin-like receptors 
(KIRs), immunoglobulin-like transcript 2 (ILT2) 
inhibitory receptors, immunoglobulin-like transcript 4 
(ILT4) and the NKG2A inhibitory receptor. New 
evidences continue to emerge that a reduced activity of 
NK cells may be related to the prevalence of inhibitory 
over activating KIR genes.
7
 
Therapeutic strategies aimed at interfering with the 
crosstalk between HRS cells and their cellular partners 
have inspired the development of new 
immunotherapies targeting different 
cellular components of the microenvironment. 
NKG2D receptor and the group of natural 
cytotoxicity receptors (NCRs) (NKp46, NKp44, and 
NKp30) are regarded as the major NK cell receptors in 
tumour defence. Immune surveillance via NKG2D and 
the corresponding ligands seems to be particularly 
effective in the early stages of tumour growth.
8
 
However, tumour cells develop escape mechanisms 
to evade NK cell surveillance and NKG2D-ligand 
interaction, which obviously results in either immune 
activation (tumour clearance) or immune silencing 
(tumour evasion).  
Silencing of NKG2D during tumour progression 
results from the persistent exposure of ligands 
expressed on the surface of target cells. Moreover, 
tumour cells release ligands into the environment by 
shedding. The soluble molecules not only block 
NKG2D, but also induce the internalization and 
degradation of the receptor.
9
 
Plasma levels of soluble ligands correlate with 
disease progression in many haematological and solid 
tumours. Former studies on NK cell function in HL 
have shown that peripheral NK cells from patients with 
HL are functionally inactive. The observed NK 
cell dysfunction correlates to elevated serum levels for 
ligands engaging NKG2D (MICA) and NKp30 
(BAG6/BAT3). Low levels of the membranous 
NKG2D-ligands, i.e. MHC class I related chain-A 
(MIC-A) and UL16 binding protein 3 (ULBP3), on 
HRS cells presents another way to escape from 
cytotoxic T-cell responses. These low levels are the 
result of proteolytic cleavage of the NKG2D-ligands by 
ERp5 and a disintegrin and metalloproteinase domain-
containing protein 10 (ADAM10) produced by HRS 
cells and mesenchymal stromal cells. Additionally, T-
cells in cHL tissue have lower NKG2D receptor 
expression levels as compared to T-cells in normal 
lymph nodes, due to TGF-β produced by the 
mesenchymal stromal and HRS cells, which blocks IL-
15-induced expression of NKG2D receptor on 
cytotoxic T-cells. Thus, the anti-tumour activity of 
CD8+ T-cells is blocked by lack of membrane 
NKG2D-ligands, release of soluble NKG2D-ligands 
and reduced NKG2D receptor levels on effector T-
cells.
10
 
Immunotherapeutic strategies targeting NK cells are 
promising because NK cell cytotoxicity could be 
restored in vitro and patients using a novel human 
antibody construct specifically designed for the 
treatment of cHL and other CD30-expressing 
malignancies. In a previous study, a tetravalent 
bispecific antibody construct (AFM13) was used to 
target CD30 on HRS cells with two of its binding sites, 
whereas the activating receptor CD16A on NK cells 
(CD30xCD16A, AFM13) was targeted by the other 
two binding sites, thereby selectively cross-
linking tumour and NK cells.
11
 
Also, epigenetic modifications have been implicated 
in the malignant phenotype of HRS cells. In this 
context, the histone-deacetylase (HDAC) inhibitor 
LBH589 (panobinostat) was shown to be clinically 
effective. LBH589 modulates the crosstalk of 
lymphocytes with HL cell lines. More specifically, 
LBH589 induces cell death, autophagy, and an increase 
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of major histocompatibility complex (MHC) class I 
chain-related genes molecules (MICA/B); that act as 
key ligands for NK cell receptors, and also favourably 
modulates the cytokine network and lymphocyte 
activity in the HL microenvironment.
12
 Studies of 
innovative therapies based on the immune system of 
HL patients treated with chemo/radiotherapy 
and targeting NK cells rather than T cells are, 
therefore, extremely promising. 
 
Lymphoid Impairment. Lymphoid anergy is well-
known in the biology and pathogenesis of cHL and T-
cell homing is central in determining the 
immunological regulation of HRS growth and 
survival.
13,14
 The lymphoid infiltrate in HL is different 
from the aspecific one detectable in reactive lymphoid 
hyperplasia (RLH), since the CD3+/CD20+ ratio is 
greater in HL than in RLH,
15
 with augmented 
CD4+CD25+ infiltrate.
15,16
 
Whole-tissue RNA analysis evaluated the specific 
microenvironment characteristics of HL, discovering 
that a great release of cytokines is present alongside 
suppressed expression of apoptotic genes and 
augmented expression of cell-cycle regulatory 
enzymes. HRS cells genotyping analysis showed a 
global suppression of principal tumor suppression 
pathways, including Rb-p16INK4, p27KIP1, p53 and 
an increased expression of components of G1-CDK 
checkpoint.
17,18
 The neoplastic HRS themselves create 
a favorable microenvironment for their survival and 
growth regulating inflammatory infiltrate. In vitro 
studies on KM-H2 HRS cell-line demonstrated that 
HRS cells are able to induce CD4+CD25+ regulatory 
T- cells (Treg),
19
 whose function is to inhibit the 
cytotoxic effects of CD8+ T-cells, the so called 
cytotoxic lymphocytes (CTL).
16,19,20
 
Main factors involved in lymphocyte migration into 
the tumor milieu include CCL20,
21
 CCL5/Rantes, IL-7, 
CCL17 and CCL22.
22
 CXCR3, CXCR4, CXCL13 and 
CCR7, and adhesion molecules including CD62 ligand 
(CD62L),are greatly expressed on T-cells of cHL 
patients.
23
 HRS cells are also able to express 
chemokine receptors useful to T-cell migration into 
tumor milieu, such as CXCL12 (receptor of CXCR4) 
and CXCR5 (receptor of CXCL13).
24
 
T-regs accumulate into the tumor milieu thanks to 
the surface expression of CCR4, the receptor for 
“thymus and activation regulated chemokine” 
(TARC/CCL17),a factor greatly secreted by HRS 
cells.
25
 T cells stimulated with TARC acquire a 
regulatory function, able to silence the cytotoxic 
activity of CTL.
26
 Conversely, CTL are not influenced 
by TARC since they lack the surface expression of 
CCR4.
27
 
Once migrated into the tumor mass, lymphocytes 
are addressed toward Th2 and T-reg differentiation (in 
particular, a Tr1 phenotype)
28
 acquiring the ability 
(together with HRS cells) to produce and secrete TGF-
 and IL-10, able to suppress CTL function. Thus, T-
regs regulate the production of IL-2 and limit CTL 
activation,
23
 while Th2 cells induce the expression of 
several cyclins and cyclin-dependent kinases 
29
 and of 
antiapoptotic markers, such as Bcl-Xl and Mcl1,
30
 with 
overexpression of STAT3 in HRS cells, activation of 
cyclin D1 and Bclx expression, and a down-regulation 
of STAT1, a tumor suppressor factor.
17,18,31
 
CTL are further silenced through the CD95-CD95L 
and PD1-PD1L cell-to-cell contact between HRS cells 
and CTL.
32-37
 Additionally, the production of galectin-
1, tissue inhibitor of metalloproteinase1 (TIMP1), and 
prostaglandin E2 (PGE2) by HRS cells inhibits CTL 
function with impairment of the IFN- production and 
induction of theTh2 and T-reg expansion.
29,38-40
 
 
Myeloid Derived Suppressor Cells. Recent 
investigations suggest that a subset of myeloid cells, 
the so called “myeloid-derived suppressor cells” 
(MDSCs) are the progenitors of tumour associated 
macrophages,
41-43
 that are considered among the most 
important and emerging prognostic factors in HL.
44
 
MDSC have been identified in solid and 
haematological cancers as a heterogeneous population 
of immature and mature cells of myeloid origin able of 
leading the tumour escape from immune-surveillance, 
through depletion of arginin and cystein due to the high 
expression level of arginase (Arg-1), nytrosylation of 
T-cell receptor, reactive oxygen species (ROS) release, 
thus being responsible of cancer progression as 
recently reviewed.
41,45,46
 The term suppressive refers to 
the peculiar ability to elicit T-cell anergy thanks to the 
above-mentioned biochemical pathways.  
In mice two distinctive mononuclear (Ly6G-, low 
“side-scattered light”-SSC) and polymorphonuclear 
(Ly6G+, high SSC) tumour-induced MDSC have been 
identified, while the phenotype in humans is still 
controversial.
47
 Overall, current evidence suggests a 
complex alteration of myeloid cell differentiation and 
function in human cancer patients that involves 
polymorphonuclear
48
 and monocytic cells.
49
 A 
frequently used combination of markers for human 
MDSC includes CD33
+
/CD11b
+
/HLA-DR
−
 and 
CD14
+
/HLA-DR
low
 to define monocytic MDSC (mo-
MDSC), CD66b
+
/CD15
+
/CD11b
+
/CD14
− 
or 
CD11b
+
/CD13
+
/CD15
+
/CD14
-
/HLA-DR
-
/Lin
-
for the 
identification of granulocytic MDSC (N-MDSC) and 
CD13
+
/CD14
-
/CD34
+
/HLA-DR
-
 for the immature 
subset MDSC (im-MDSC).  
T cell dysfunction induced by MDSC can reflect the 
recruitment of inflammatory cells and favour the 
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aberrant MDSC production, setting up a pathological 
loop.
45
 
Our group hypothesized that the amount of MDSC 
in peripheral blood of cHL-patients may reflect the 
complexity of cytokine and cell-cell contacts of the 
pathologic neoplastic microenvironment and that the 
myeloid cellular impairment could represent a 
prognostic factor in cHL at diagnosis. Preliminary data 
from our single-centre small series of 60 newly 
diagnosed cHL-patients identify an increase of the 
absolute count of im-MDSC, N-MDSC and mo-MDSC 
in peripheral blood at diagnosis (Romano, manuscript 
submitted). 
Progression free survival of patients carrying high 
levels of MDSC at baseline was poor. In multivariate 
analysis, im-MDSC high levels were an independent 
predictor of inferior outcome despite a PET-2 based 
risk adapted treatment (Romano, manuscript 
submitted).  
 
Soluble Factors.  
TARC. The CC chemokine ligand 17 (CCL17), also 
well-known as Thymus and Activation-Regulated 
Chemokine (TARC),is a member of the CC chemokine 
group constitutively expressed in the thymus. TARC is 
produced by monocyte-derived dendritic cells and 
binds specifically to the CC chemokine receptor 4 
(CCR4), mainly expressed on T-regs and Th2 cells of 
the reactive infiltrate.
50
 TARC is considered a Th2-type 
chemokine because CCR4-expressing T cells mainly 
produce interleukin (IL)-4. 
In more than 90% of cases HL lymph-nodes have a 
positive TARC staining in HRS cells detected by 
immunohistochemistry, with high specificity for HL 
since the low/absent expression in anaplastic large cell 
lymphoma or T-cell-rich B-cell lymphoma. 
In about 85% of patients, TARC is detectable and 
elevated in serum at diagnosis before treatment.
51,52
 
Pre-treatment serum TARC levels correlate with stage 
of disease, erythrocyte sedimentation rate, leukocyte 
and lymphocyte counts,
51,52
 pre-treatment metabolic 
tumor volume, as measured by quantification of 2-
[18F]fluoro-2-deoxyglucose positron emission 
tomography images, and to treatment response.
53
 
HLA-G. The expression of non-classical Human 
leukocyte antigen G (HLA-G) is another strategy 
adopted by HRS cells to evade immune defence and to 
create protected niches where they grow and expand. 
HLA-G is expressed on HRS cells in more than 50% 
of HL patients and is associated with lack of HLA class 
I expression and tumour cell EBV status. HLA-G is a 
non-classical major histocompatibility complex (MHC) 
Class I product with limited sequence variability. The 
HLA-G gene generates seven isoforms by alternative 
splicing encoding HLA-G1, -G2, -G3, and -G4 
membrane-bound protein isoforms and HLA-G5, -G6, 
and -G7 soluble protein isoforms.  
The properties of soluble and membrane-bound 
HLA-G proteins are different, but in general, both are 
regarded as being immunosuppressive.
54
 
HLA-G is a tolerogenic molecule which inhibits 
cytolysis mediated by NK cells or T lymphocytes, 
induces T cell apoptosis and blocks transendothelial 
migration of NK cells and these roles are performed 
upon binding the KIR2DL4 and the ILT2 and ILT4 
ligands.
55
 
It is known that antigen-presenting cells expressing 
membranous HLA-G can induce regulatory T cells in 
freshly isolated peripheral blood mononuclear cells, in 
vitro and that soluble HLA-G induces regulatory 
T cells in an antigen non-specific manner.
56
 
The latter can inhibit CTL responses and is present 
in the cHL reactive infiltrate.
57
 Alterations in HLA-G 
antigen expression and function are often induced in 
tumours and are likely to be mediated by various 
microenvironmental factors. Interestingly, 
immunohistochemistry and flow cytometry evaluations 
have shown expression of HLA-G protein in a large 
number of solid and some hematopoietic malignancies, 
e.g. cutaneous lymphomas, chronic lymphocytic 
leukemia (CLL) and diffuse large B-cell lymphoma. In 
CLL, some B-cell, T-cell non-Hodgkin’s lymphomas, 
and leukemia, plasma levels of soluble HLA-G are 
increased. Soluble HLA-G serum and plasma levels 
have been useful markers for the prediction of some 
of these malignancies.
57
 
A population-based study showed that protein 
expression of HLA-G by HRS cells is common at 
primary cHL diagnosis and that this expression is 
associated with lack of EBV and absence of cell 
surface expression of MHC Ia on HRS cells. The 
consequence of HLA-G expression or sHLA-G is an 
escape from T and NK cell-mediated recognition. 
Thus, alterations of non-classical and classical 
HLA class I antigens and components of the antigen-
processing pathway provide tumour cells with different 
mechanisms to inactivate immune responses resulting 
in tumour growth and evasion from host 
immune surveillance.
7
 
sCD163. Recently, an increasing interest has been 
focused on the amount of CD68+ tumor associated 
macrophages (TAM) infiltration.
44
 The amount of 
TAM is strongly associated with shortened survival in 
cHL, correlated with likelihood of relapse after 
autologous stem cell transplantation and outperformed 
the current International Prognostic Score (IPS) for 
disease-specific survival.
44
 
The functional characterization of TAM is still to be 
performed and, possibly, differences in survival among 
patients could be explained by the macrophages 
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M1/M2 binary on which these cells differentiate, or by 
the histological signature of myeloid derived 
immunosuppression. Increasing evidences in mammary 
tumor model suggests that the most 
immunosuppressive activity is played by TAM derived 
from circulating MDSC, but it is still an open question. 
The antigen CD163 is physiologically expressed on 
the macrophage surface, and it is currently investigated 
as an additional marker of macrophage infiltration in 
HL microenvironment, since the lack of reproducibility 
of CD68 staining. An increased infiltration of 
CD163/CD68 (M2 macrophages) was associated to 
poor outcome, with a rise in treatment-related deaths 
and poor event-free survival, disease-specific survival 
and overall survival.
58
 Recently, the circulating fraction 
of CD163 in serum (s-CD163) has been evaluated in 
patients at diagnosis and relapse, showing not being 
inferior to TARC to identify patients with poor 
outcome.
59
 
 
Conclusions. Despite high initial cure rate, almost 20% 
of cHL patients fails front line therapy and have a 
median overall survival less than three years. 
Increasing evidences suggest that failure to 
conventional therapy is not only due to the intrinsic 
resistance of HRS cell but accessory cells and the so 
called microenvironment play an important role. The 
network and the relationship between the HRS and 
accessory cells are not fully elucidated, but several 
studies have highlighted new pathways that currently 
are under investigation as prognostic markers, 
including HLA-G, s-CD163 and MDSC. In addition, 
new immunological target are emerging in cHL 
microenvironment, including NK, NKT and MDSC 
that in the future could be treated with specific drugs. 
Actually, the introduction of targeted immunotherapy 
has induced an increasing interest about the prognostic 
implication of the microenvironment and its 
manipulation with drugs able to elicit an immune 
response. 
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